SB 939

• CAT Number: I005525
• CAS Number: 929016-96-6
• Molecular Formula: C₂₀H₃₀N₄O₂
• Molecular Weight: 358.48
• Purity: ≥95%
• Synonyms: SB939;SB-939;SB 939
• Target: HDAC
• Solubility: DMSO ≥70mg/mL Water <1.2mg/mL Ethanol ≥70mg/mL
• Storage: Store at -20°C
• IC50: 49 nM(HDAC1); 43 nM(HDAC3); 56 nM(HDAC4); 47 nM(HDAC5); 70 nM(HDAC9); 40 nM(HDAC10)
• IUPAC Name: (E)-3-[2-butyl-1-[2-(diethylamino)ethyl]benzimidazol-5-yl]-N-hydroxyprop-2-enamide
• InChI: InChI=1S/C20H30N4O2/c1-4-7-8-19-21-17-15-16(10-12-20(25)22-26)9-11-18(17)24(19)14-13-23(5-2)6-3/h9-12,15,26H,4-8,13-14H2,1-3H3,(H,22,25)/b12-10+
• InChIKey: JHDKZFFAIZKUCU-ZRDIBKRKSA-N
• SMILES: CCCCC1=NC2=C(N1CCN(CC)CC)C=CC(=C2)C=CC(=O)NO

SB 939（Cat No.:I005525）is a potent, orally bioavailable histone deacetylase (HDAC) inhibitor with promising anticancer properties. It targets multiple HDAC enzymes, leading to increased acetylation of histones and non-histone proteins, which results in altered gene expression, cell cycle arrest, and apoptosis in cancer cells. SB 939 has shown efficacy in preclinical models for various cancers, including leukemia, lymphoma, and solid tumors. Its oral availability and selective inhibition make it a valuable candidate in cancer therapy, offering a potential therapeutic option for targeting epigenetic dysregulation in malignancies.

Reference

1:Phase 2, randomized, double-blind study of pracinostat in combination with azacitidine in patients with untreated, higher-risk myelodysplastic syndromes. Garcia-Manero G, Montalban-Bravo G, Berdeja JG, Abaza Y, Jabbour E, Essell J, Lyons RM, Ravandi F, Maris M, Heller B, DeZern AE, Babu S, Wright D, Anz B, Boccia R, Komrokji RS, Kuriakose P, Reeves J, Sekeres MA, Kantarjian HM, Ghalie R, Roboz GJ.Cancer. 2017 May 15;123(6):994-1002. doi: 10.1002/cncr.30533. Epub 2017 Jan 17. PMID: 28094841 2:Activating Transcription Factor 3 Expression as a Marker of Response to the Histone Deacetylase Inhibitor Pracinostat. Sooraj D, Xu D, Cain JE, Gold DP, Williams BR.Mol Cancer Ther. 2016 Jul;15(7):1726-39. doi: 10.1158/1535-7163.MCT-15-0890. Epub 2016 Apr 25. PMID: 27196751 3:Histone deacetylase inhibitor pracinostat in doublet therapy: a unique strategy to improve therapeutic efficacy and to tackle herculean cancer chemoresistance. Ganai SA.Pharm Biol. 2016 Sep;54(9):1926-35. doi: 10.3109/13880209.2015.1135966. Epub 2016 Feb 5. Review. PMID: 26853619 4:Orphan drug designation for pracinostat, volasertib and alvocidib in AML. Bose P, Grant S.Leuk Res. 2014 Aug;38(8):862-5. doi: 10.1016/j.leukres.2014.06.007. Epub 2014 Jun 17. No abstract available. PMID: 24996975 5:A phase I study of histone deacetylase inhibitor, pracinostat (SB939), in pediatric patients with refractory solid tumors: IND203 a trial of the NCIC IND program/C17 pediatric phase I consortium. Zorzi AP, Bernstein M, Samson Y, Wall DA, Desai S, Nicksy D, Wainman N, Eisenhauer E, Baruchel S.Pediatr Blood Cancer. 2013 Nov;60(11):1868-74. doi: 10.1002/pbc.24694. Epub 2013 Jul 25. PMID: 23893953 6:The oral HDAC inhibitor pracinostat (SB939) is efficacious and synergistic with the JAK2 inhibitor pacritinib (SB1518) in preclinical models of AML. Novotny-Diermayr V, Hart S, Goh KC, Cheong A, Ong LC, Hentze H, Pasha MK, Jayaraman R, Ethirajulu K, Wood JM.Blood Cancer J. 2012 May;2(5):e69. doi: 10.1038/bcj.2012.14. Epub 2012 May 4. PMID: 22829971 Free PMC Article7:Therapy with the histone deacetylase inhibitor pracinostat for patients with myelofibrosis. Quintás-Cardama A, Kantarjian H, Estrov Z, Borthakur G, Cortes J, Verstovsek S.Leuk Res. 2012 Sep;36(9):1124-7. doi: 10.1016/j.leukres.2012.03.003. Epub 2012 Apr 2. PMID: 22475363 Free PMC Article8:Preclinical metabolism and disposition of SB939 (Pracinostat), an orally active histone deacetylase inhibitor, and prediction of human pharmacokinetics. Jayaraman R, Pilla Reddy V, Pasha MK, Wang H, Sangthongpitag K, Yeo P, Hu CY, Wu X, Xin L, Goh E, New LS, Ethirajulu K.Drug Metab Dispos. 2011 Dec;39(12):2219-32. doi: 10.1124/dmd.111.041558. Epub 2011 Aug 26. PMID: 21873472 Free Article